Compare Adaptive Biotechnologies Corp (ADPT) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Global X Robo Global Robotics & Automation ETF — how do they compare? Adaptive Biotechnologies Corp trades at $20.12 (market cap $3.33B), while Global X Robo Global Robotics & Automation ETF trades at $80.55. The key difference: Adaptive Biotechnologies Corp is trading nearer its 52-week high, Global X Robo Global Robotics & Automation ETF nearer its low. Which is the better fit depends on your goals.
| ADPT | ROBO | |
|---|---|---|
Market Cap | $3.33B | — |
Sector | Health | Sector/Thematic |
52-Week High | $22.37 | $90.34 |
52-Week Low | $10.24 | $60.15 |
Enterprise Value | $3.19B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
ROBO trades at $86.19, up 3.36% today, with a bullish technical signal from moving averages and neutral oscillators. Recent news highlights the ETF's rebalancing toward AI infrastructure and physical automation themes, positioning it to benefit from the expanding robotics and AI ecosystem. Key support lies at $85, with resistance at $87.
The outlook is positive, driven by thematic tailwinds in robotics and AI infrastructure, though valuation metrics are unavailable. Risks include cyclical exposure and reliance on AI adoption. Analyst sentiment is cautiously optimistic, with institutional interest growing in physical AI themes.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
